VASCONCELLES MICHAEL 4
4 · Kura Oncology, Inc. · Filed Jun 4, 2026
Research Summary
AI-generated summary of this filing
Kura Oncology Director Michael Vasconcelles Receives 35,000-Share Option Award
What Happened
Michael Vasconcelles, a director of Kura Oncology (KURA), received a derivative award on 2026-06-04: a grant of options covering 35,000 shares. The reported acquisition price is $0.00, indicating this was an award/option grant rather than an open-market purchase.
Key Details
- Transaction date: 2026-06-04; transaction type: A (Award/Grant of a derivative).
- Shares/options granted: 35,000; reported price: $0.00 (award/derivative reporting).
- Shares owned after the transaction: not specified in the filing.
- Footnote: the option vests in full on the one-year anniversary of the grant date.
- Filing timeliness: Form 4 filed same day as the transaction (no late filing indicated).
Context
This is a compensation-related option grant, not a purchase or sale of stock. Such awards are common for directors and reflect equity compensation rather than an immediate market position — they do not indicate an immediate cash inflow or sale. Vesting and any future exercise (and exercise price, if disclosed later) will determine when the director can convert these options into shares.
Insider Transaction Report
- Award
Option to purchase common stock
[F1]2026-06-04+35,000→ 35,000 totalExercise: $8.77Exp: 2036-06-03→ Common Stock (35,000 underlying)
Footnotes (1)
- [F1]This option vests in full on the one year anniversary of the date of grant.